JPH0214039B2 - - Google Patents
Info
- Publication number
- JPH0214039B2 JPH0214039B2 JP56112913A JP11291381A JPH0214039B2 JP H0214039 B2 JPH0214039 B2 JP H0214039B2 JP 56112913 A JP56112913 A JP 56112913A JP 11291381 A JP11291381 A JP 11291381A JP H0214039 B2 JPH0214039 B2 JP H0214039B2
- Authority
- JP
- Japan
- Prior art keywords
- lymphotoxin
- cells
- human
- animal
- derived
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 102000004083 Lymphotoxin-alpha Human genes 0.000 claims description 94
- 108090000542 Lymphotoxin-alpha Proteins 0.000 claims description 94
- 241001465754 Metazoa Species 0.000 claims description 44
- 238000004519 manufacturing process Methods 0.000 claims description 20
- 238000000338 in vitro Methods 0.000 claims description 14
- 241000282412 Homo Species 0.000 claims description 10
- 210000001124 body fluid Anatomy 0.000 claims description 7
- 239000010839 body fluid Substances 0.000 claims description 7
- 238000009792 diffusion process Methods 0.000 claims description 7
- 239000000411 inducer Substances 0.000 claims description 5
- 238000001727 in vivo Methods 0.000 claims description 3
- 238000000746 purification Methods 0.000 claims description 3
- 229920002684 Sepharose Polymers 0.000 claims description 2
- 238000001042 affinity chromatography Methods 0.000 claims description 2
- 238000002360 preparation method Methods 0.000 claims description 2
- 210000004027 cell Anatomy 0.000 description 93
- 230000000694 effects Effects 0.000 description 23
- 238000000034 method Methods 0.000 description 14
- 206010028980 Neoplasm Diseases 0.000 description 11
- 238000011580 nude mouse model Methods 0.000 description 10
- 235000015097 nutrients Nutrition 0.000 description 9
- 241000699660 Mus musculus Species 0.000 description 7
- 241000699800 Cricetinae Species 0.000 description 6
- 108010047620 Phytohemagglutinins Proteins 0.000 description 6
- 201000011510 cancer Diseases 0.000 description 6
- 230000001939 inductive effect Effects 0.000 description 6
- 239000002609 medium Substances 0.000 description 6
- 239000002504 physiological saline solution Substances 0.000 description 6
- 230000001885 phytohemagglutinin Effects 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 206010003445 Ascites Diseases 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 241000700159 Rattus Species 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 235000013601 eggs Nutrition 0.000 description 4
- 230000001965 increasing effect Effects 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 229940124597 therapeutic agent Drugs 0.000 description 4
- 238000002054 transplantation Methods 0.000 description 4
- 102000016605 B-Cell Activating Factor Human genes 0.000 description 3
- 108010028006 B-Cell Activating Factor Proteins 0.000 description 3
- 102000014150 Interferons Human genes 0.000 description 3
- 108010050904 Interferons Proteins 0.000 description 3
- 210000000683 abdominal cavity Anatomy 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 238000005194 fractionation Methods 0.000 description 3
- 238000002523 gelfiltration Methods 0.000 description 3
- 230000008105 immune reaction Effects 0.000 description 3
- 229940079322 interferon Drugs 0.000 description 3
- 210000000265 leukocyte Anatomy 0.000 description 3
- 210000004379 membrane Anatomy 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 210000003200 peritoneal cavity Anatomy 0.000 description 3
- 239000008363 phosphate buffer Substances 0.000 description 3
- 230000002062 proliferating effect Effects 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 241000287828 Gallus gallus Species 0.000 description 2
- 102000008072 Lymphokines Human genes 0.000 description 2
- 108010074338 Lymphokines Proteins 0.000 description 2
- 241000711408 Murine respirovirus Species 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 230000024932 T cell mediated immunity Effects 0.000 description 2
- 210000004102 animal cell Anatomy 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 235000013330 chicken meat Nutrition 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 231100000433 cytotoxic Toxicity 0.000 description 2
- 230000001472 cytotoxic effect Effects 0.000 description 2
- 238000000502 dialysis Methods 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 210000005260 human cell Anatomy 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 239000003226 mitogen Substances 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 238000005185 salting out Methods 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- HBOMLICNUCNMMY-KJFJCRTCSA-N 1-[(4s,5s)-4-azido-5-(hydroxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione Chemical compound O=C1NC(=O)C(C)=CN1C1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 HBOMLICNUCNMMY-KJFJCRTCSA-N 0.000 description 1
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 241000272201 Columbiformes Species 0.000 description 1
- 108010062580 Concanavalin A Proteins 0.000 description 1
- 102000012410 DNA Ligases Human genes 0.000 description 1
- 108010061982 DNA Ligases Proteins 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 208000006552 Lewis Lung Carcinoma Diseases 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 208000002495 Uterine Neoplasms Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 239000007640 basal medium Substances 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 238000003163 cell fusion method Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000003795 desorption Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 210000002257 embryonic structure Anatomy 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 230000035931 haemagglutination Effects 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 230000001678 irradiating effect Effects 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 108010086662 phytohemagglutinin-M Proteins 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 235000015277 pork Nutrition 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- -1 ribopolysaccharide Substances 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 206010046766 uterine cancer Diseases 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Landscapes
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Priority Applications (14)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP56112913A JPS5816687A (ja) | 1981-07-21 | 1981-07-21 | リンホトキシンの製造方法 |
| FR8212541A FR2513124B1 (fr) | 1981-07-21 | 1982-07-19 | Production et applications du facteur de lyse des cellules-cibles |
| SE8204382A SE8204382L (sv) | 1981-07-21 | 1982-07-19 | Sett att framstella malcellysfaktor och anvendning derav |
| KR8203215A KR870001433B1 (ko) | 1981-07-21 | 1982-07-20 | 적상적혈구(的狀赤血球) 붕괴인자의 제조 방법 |
| AU86200/82A AU560793B2 (en) | 1981-07-21 | 1982-07-20 | Production of target cell lysis factor |
| CH4420/82A CH664974A5 (fr) | 1981-07-21 | 1982-07-20 | Production du facteur de lyse des cellules-cibles. |
| IT48855/82A IT1196549B (it) | 1981-07-21 | 1982-07-20 | Procedimento per la produzione del fattore di lisi cellule bersaglio (tclf),prodotto ottenuto a suo impiego in terapia clinica,in particolare come agente citolitico antitumurale |
| US06/400,487 US4495282A (en) | 1981-07-21 | 1982-07-21 | Process for producing target cell lysis factor and uses therewith |
| AT0283582A AT387980B (de) | 1981-07-21 | 1982-07-21 | Verfahren zur herstellung eines die aufloesung menschlicher zellen bewirkenden faktors |
| GB08221100A GB2106117B (en) | 1981-07-21 | 1982-07-21 | Process for producing target cell lysis factor |
| ES514210A ES514210A0 (es) | 1981-07-21 | 1982-07-21 | Un procedimiento para la produccion de tclf. |
| DE3227262A DE3227262C3 (de) | 1981-07-21 | 1982-07-21 | Verfahren zur Herstellung von menschlichem Tumor-Nekrose-Faktor und menschlicher Tumor-Nekrose-Faktor |
| DE3249946A DE3249946C2 (de) | 1981-07-21 | 1982-07-21 | hTNF-haltiges therapeutisches Mittel gegen maligne Tumoren und dessen Verwendung |
| SE9000532A SE9000532L (sv) | 1981-07-21 | 1990-02-14 | Farmaceutisk tclf-komposition |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP56112913A JPS5816687A (ja) | 1981-07-21 | 1981-07-21 | リンホトキシンの製造方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS5816687A JPS5816687A (ja) | 1983-01-31 |
| JPH0214039B2 true JPH0214039B2 (zh) | 1990-04-05 |
Family
ID=14598617
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP56112913A Granted JPS5816687A (ja) | 1981-07-21 | 1981-07-21 | リンホトキシンの製造方法 |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS5816687A (zh) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5821621A (ja) * | 1981-07-31 | 1983-02-08 | Hayashibara Biochem Lab Inc | ヒトツモア・ネクロシス・ファクタ−を含有する悪性腫瘍治療剤 |
| JPH0764744B2 (ja) * | 1981-11-21 | 1995-07-12 | 株式会社林原生物化学研究所 | 標的細胞障害性因子とヒトインタ−フェロンとを有効成分として含有する悪性腫瘍治療剤 |
| JPS5889195A (ja) * | 1981-11-21 | 1983-05-27 | Hayashibara Biochem Lab Inc | 標的細胞障害性因子の製造方法 |
| JP2518635B2 (ja) * | 1981-07-31 | 1996-07-24 | 株式会社 林原生物化学研究所 | ヒト ツモア・ネクロシス・フアクタ− |
| JP2518634B2 (ja) * | 1981-07-31 | 1996-07-24 | 株式会社 林原生物化学研究所 | ヒト ツモア・ネクロシス・フアクタ−の製造方法 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5498307A (en) * | 1978-01-22 | 1979-08-03 | Hayashibara Takeshi | Production of interferon |
-
1981
- 1981-07-21 JP JP56112913A patent/JPS5816687A/ja active Granted
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5498307A (en) * | 1978-01-22 | 1979-08-03 | Hayashibara Takeshi | Production of interferon |
Also Published As
| Publication number | Publication date |
|---|---|
| JPS5816687A (ja) | 1983-01-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4621050A (en) | Process for the production of human colony-stimulating factor | |
| JPS631296B2 (zh) | ||
| JPS6045849B2 (ja) | ヒトエリトロポエチンの製造方法 | |
| JPS585671B2 (ja) | ヒト卵胞刺激ホルモンの製造方法 | |
| JPS5852634B2 (ja) | ウロキナ−ゼの製造法 | |
| JPS586475B2 (ja) | ヒト絨毛性性腺刺激ホルモンの製造方法 | |
| JPH0214039B2 (zh) | ||
| JPS58107197A (ja) | ツモアネクロシスフアクタ−の製造方法 | |
| JPS6045848B2 (ja) | ヒト成長ホルモンの製造方法 | |
| JPS5823793A (ja) | ヒトｔ細胞増殖因子の製造方法 | |
| JPS6245208B2 (zh) | ||
| JP2926409B2 (ja) | 癌転移抑制因子の製造方法 | |
| JPH0446928B2 (zh) | ||
| CA1295241C (en) | Lymphokine and its production and uses | |
| JPS5888322A (ja) | 標的細胞障害性因子を含有する悪性腫瘍治療剤とその製造方法 | |
| KR830001817B1 (ko) | 타이프ⅱ 인터페론의 제조방법 | |
| JP2532025B2 (ja) | 新リンホカインｉｉｉを有効成分とする抗腫瘍作用を有するリンホカインの活性増強剤 | |
| KR820001174B1 (ko) | 사람 특이성 인터페론의 제조법 | |
| JPS6045850B2 (ja) | ヒト副腎皮質刺激ホルモンの製法 | |
| JP2518635B2 (ja) | ヒト ツモア・ネクロシス・フアクタ− | |
| JPH0523755B2 (zh) | ||
| JPH0214038B2 (zh) | ||
| JPH0526468B2 (zh) | ||
| JPS62236495A (ja) | ヒト ツモア・ネクロシス・フアクタ−の製造方法 | |
| JPS61115099A (ja) | モノクロ−ナル抗体とその製法 |